Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1237456 | 1.00 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Trifluoroacetic Acid SCHEMBL1238927 | 1.00 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL909503 | 0.94 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL909505 | 0.94 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1655829 | 0.94 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Trifluoroacetic Acid SCHEMBL1237789 | 0.90 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Trifluoroacetic Acid SCHEMBL1237792 | 0.90 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1237459 | 0.89 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1238929 | 0.89 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Trifluoroacetic Acid SCHEMBL4323538 | 0.88 | KCNH2 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992618-B1 | POLYCYCLIC CINNAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-7973033-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2011-05-12 | — | — | US | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7923563-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7897632-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100168095-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2010-07-01 | — | — | US | disclosed |
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048448-A1 | SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| EP-1992618-A1 | POLYCYCLIC CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1953151-A1 | SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-09-20 | — | — | US | disclosed |
| EP-1808432-A1 | AMORPHOUS OBJECT OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-07-18 | — | — | EP | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086860-A1 | COMPOUND | ARRB1, NR3C2, ADRA2C | PSEN1 3654/4885PSEN2 3277/4885APH1B 2478/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | PSEN1 3275/4885PSEN2 3796/4885APH1B 2344/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | PSEN1 2883/4885PSEN2 3879/4885APH1B 937/4885 |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 13/4885 |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | BACE1, APP, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 13/4885 |
| US-20100168095-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 13/4885 |
| US-20090048448-A1 | SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF | APP, BACE1, BACE2 | PSEN1 25/4885PSEN2 16/4885APH1B 34/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | PSEN1 1/4885PSEN2 4/4885APH1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.